These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 12396538

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Social support and quality of life over time among adults living with HIV in the HAART era.
    Burgoyne R, Renwick R.
    Soc Sci Med; 2004 Apr; 58(7):1353-66. PubMed ID: 14759681
    [Abstract] [Full Text] [Related]

  • 3. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM, Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [Abstract] [Full Text] [Related]

  • 4. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 5. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.
    Kempen JH, Martin BK, Wu AW, Barron B, Thorne JE, Jabs DA, Studies of Ocular Complications of AIDS Researh Group.
    Ophthalmology; 2003 May 01; 110(5):987-95. PubMed ID: 12750102
    [Abstract] [Full Text] [Related]

  • 6. Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile.
    Burgoyne RW, Rourke SB, Behrens DM, Salit IE.
    AIDS Behav; 2004 Jun 01; 8(2):151-63. PubMed ID: 15187477
    [Abstract] [Full Text] [Related]

  • 7. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.
    Powers AE, Marden SF, McConnell R, Leidy NK, Campbell CM, Soeken KL, Barker C, Davey RT, Dybul MR.
    AIDS; 2006 Apr 04; 20(6):837-45. PubMed ID: 16549967
    [Abstract] [Full Text] [Related]

  • 8. Quality of life and its correlates in HIV/AIDS male outpatients receiving highly active antiretroviral therapy in Taiwan.
    Yen CF, Tsai JJ, Lu PL, Chen YH, Chen TC, Chen PP, Chen TP.
    Psychiatry Clin Neurosci; 2004 Oct 04; 58(5):501-6. PubMed ID: 15482581
    [Abstract] [Full Text] [Related]

  • 9. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 10. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR, Chaisson RE, Keruly J, Moore RD.
    J Infect Dis; 2003 Dec 01; 188(11):1659-65. PubMed ID: 14639536
    [Abstract] [Full Text] [Related]

  • 11. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.
    Zorrilla CD, Santiago LE, Knubson D, Liberatore K, Estronza G, Colón O, Acevedo M.
    Cell Mol Biol (Noisy-le-grand); 2003 Dec 01; 49(8):1187-92. PubMed ID: 14983985
    [Abstract] [Full Text] [Related]

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 01; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A, Spanish Group of Paediatric HIV Infection.
    Clin Infect Dis; 2006 Mar 15; 42(6):862-9. PubMed ID: 16477566
    [Abstract] [Full Text] [Related]

  • 14. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 15. Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre.
    Schrooten W, Florence E, Dreezen C, Van Esbroeck M, Fransen K, Alonso A, Desmet P, Colebunders R, Kestens L, De Roo A.
    Int J STD AIDS; 2004 Aug 15; 15(8):523-8. PubMed ID: 15307962
    [Abstract] [Full Text] [Related]

  • 16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.
    AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069
    [Abstract] [Full Text] [Related]

  • 17. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 18. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.
    Antivir Ther; 2004 Oct 01; 9(5):713-9. PubMed ID: 15535408
    [Abstract] [Full Text] [Related]

  • 19. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.
    J Infect Dis; 2004 Nov 15; 190(10):1860-8. PubMed ID: 15499544
    [Abstract] [Full Text] [Related]

  • 20. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.
    Int J Urol; 2006 Sep 15; 13(9):1202-6. PubMed ID: 16984553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.